surmount-1 tirzepatide trial obesity without diabetes Early‐Onset and Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials - Gourgari - 2025 - Obesity New GLP-1 clinical trial data
Description
In SURMOUNT-1, adults with obesity or overweight without diabetes experienced substantial weight reduction over 72 weeks
The choice between the two medications should involve a thorough evaluation by a healthcare provider, considering factors like your overall health, specific weight loss goals, medication tolerance, and any underlying medical conditions
Accessed 13 May 2022
And lifestyle changes are important in helping patients maintain their progress after theyve reached their goal weight
The lifestyle changes need to be
"FDA guidance clearly authorizes the latter, but the former is to a certain degree in the eye of the beholder
